[Hormone replacement therapy and cardiovascular pathology in menopause]

Area of Science:

• Cardiovascular Science
• Endocrinology
• Public Health

Context:

• Vascular disease incidence rises with age, but the increase in women aged 50-60 is not solely linked to menopause.
• Postmenopausal women exhibit altered lipid metabolism and hemostatic system risk factors.
• Previous studies on hormone replacement therapy (HRT) often excluded diverse populations, limiting generalizability.

Purpose:

• To review the current understanding of menopausal effects on cardiovascular disease (CVD) risk factors.
• To evaluate the existing evidence for hormone replacement therapy's (HRT) impact on CVD in postmenopausal women.
• To highlight the need for further research, including large-scale randomized trials, to definitively assess HRT's role in CVD prevention.

Summary:

• While menopause itself may not directly correlate with increased vascular disease risk between ages 50-60, significant changes in lipid metabolism and hemostasis are observed postmenopause.
• Existing data suggest beneficial effects of HRT on cardiovascular health in postmenopausal women.
• Ongoing large-scale studies like the Women's Health Initiative and Heart Estrogen/Progestin Replacement Study are expected to provide definitive evidence on HRT's utility for primary and secondary CVD prevention.

Impact:

• Informs clinical practice regarding cardiovascular risk assessment and management in postmenopausal women.
• Guides future research directions in menopausal health and cardiovascular disease prevention.
• Contributes to evidence-based recommendations for hormone replacement therapy use in women.
• Highlights limitations of past research and the importance of diverse population representation in clinical studies.